P
5.99
0.92 (18.15%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Personalis, Inc. | Bullish | Mixed |
Stockmoo Score
0.3
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (HC Wainwright & Co., 50.25%) | Buy |
| Median | 7.25 (21.04%) | |
| Low | 7.00 (BTIG, 16.86%) | Buy |
| Average | 7.75 (29.38%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 5.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Aug 2024 | 9.00 (50.25%) | Buy | 5.84 |
| BTIG | 16 Aug 2024 | 7.00 (16.86%) | Buy | 5.99 |
| Needham | 16 Aug 2024 | 7.25 (21.04%) | Buy | 5.99 |
| 21 Jun 2024 | 3.50 (-41.57%) | Buy | 1.22 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Sep 2024 | Announcement | ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test |
| 22 Aug 2024 | Announcement | Personalis to Participate at Upcoming Investor Conferences |
| 19 Aug 2024 | Announcement | Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 16 Aug 2024 | Announcement | Personalis and Tempus Announce Expanded Collaboration |
| 07 Aug 2024 | Announcement | Personalis Reports Second Quarter 2024 Financial Results |
| 31 Jul 2024 | Announcement | Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference |
| 24 Jul 2024 | Announcement | Personalis to Announce Second Quarter 2024 Financial Results |
| 11 Jul 2024 | Announcement | Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing |
| 18 Jun 2024 | Announcement | Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |